Physician profile
Renee Dodd
NPI 1134278609
$2,354.41
in general payments reported to CMS, 2019-2025
27 companies · $29.40 in 2025
The $29.40 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,901 · 2022: $363 · 2023: $43.41 · 2024: $17.31 · 2025: $29.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.70 | 2021-2025 | |
| Novo Nordisk INC | $215.29 | 2021-2022 | |
| Esperion Therapeutics, INC. | $208.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.76 | 2021-2022 | |
| Lilly USA, LLC | $155.26 | 2021-2022 | |
| Dexcom, INC. | $142.76 | 2021-2022 | |
| Amarin Pharma, INC. | $138.34 | 2021-2022 | |
| Pfizer INC. | $128.31 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $90.89 | 2021-2022 | |
| Eisai INC. | $84.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $71.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $67.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $58.00 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.83 | 2021 | |
| Abbott Laboratories | $54.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.87 | 2021 | |
| Exact Sciences Corporation | $36.98 | 2023-2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $34.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.50 | 2022 | |
| Myocardial Solutions, INC. | $28.04 | 2021 | |
| Cvrx, INC. | $23.74 | 2023 | Barostim Neo System |
| Mylan Specialty L.P. | $20.91 | 2021 | |
| Glaxosmithkline, LLC. | $16.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2021 | |
| Ibsa Pharma INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.